These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 20865640

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Plasmatherapy in atypical hemolytic uremic syndrome.
    Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T.
    Semin Thromb Hemost; 2010 Sep; 36(6):673-81. PubMed ID: 20865645
    [Abstract] [Full Text] [Related]

  • 44. Atypical haemolytic uraemic syndrome.
    Kavanagh D, Goodship TH, Richards A.
    Br Med Bull; 2006 Sep; 77-78():5-22. PubMed ID: 16968692
    [Abstract] [Full Text] [Related]

  • 45. Pathophysiology and management of thrombotic microangiopathies.
    Ruggenenti P, Remuzzi G.
    J Nephrol; 1998 Sep; 11(6):300-10. PubMed ID: 10048496
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
    Saunders RE, Abarrategui-Garrido C, Frémeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, López Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodríguez de Córdoba S, Sánchez-Corral P, Skerka C, Zipfel PF, Perkins SJ.
    Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
    [Abstract] [Full Text] [Related]

  • 49. Update on evaluating complement in hemolytic uremic syndrome.
    Kavanagh D, Goodship TH.
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):565-71. PubMed ID: 18089972
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
    Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA.
    J Immunol; 2015 Jun 01; 194(11):5129-38. PubMed ID: 25917093
    [Abstract] [Full Text] [Related]

  • 52. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.
    Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V.
    J Am Soc Nephrol; 2010 Dec 01; 21(12):2180-7. PubMed ID: 21051740
    [Abstract] [Full Text] [Related]

  • 53. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes.
    Dragon-Durey MA, Frémeaux-Bacchi V.
    Springer Semin Immunopathol; 2005 Nov 01; 27(3):359-74. PubMed ID: 16189652
    [Abstract] [Full Text] [Related]

  • 54. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
    Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R.
    J Immunol; 2009 May 15; 182(10):6394-400. PubMed ID: 19414792
    [Abstract] [Full Text] [Related]

  • 55. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment.
    Hofer J, Giner T, Józsi M.
    Semin Thromb Hemost; 2014 Jun 15; 40(4):431-43. PubMed ID: 24799303
    [Abstract] [Full Text] [Related]

  • 56. Three kidneys, two diseases, one antibody?
    Lorcy N, Rioux-Leclercq N, Lombard ML, Le Pogamp P, Vigneau C.
    Nephrol Dial Transplant; 2011 Nov 15; 26(11):3811-3. PubMed ID: 21813829
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Cobalamin c deficiency associated with antifactor h antibody-associated hemolytic uremic syndrome in a young adult.
    Philipponnet C, Desenclos J, Brailova M, Aniort J, Kemeny JL, Deville C, Fremeaux-Bacchi V, Souweine B, Heng AE.
    BMC Nephrol; 2020 Mar 12; 21(1):96. PubMed ID: 32164588
    [Abstract] [Full Text] [Related]

  • 60. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
    Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF.
    Blood; 2007 Sep 01; 110(5):1516-8. PubMed ID: 17495132
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.